R&D NewCo

Takeda announces Takeda-PRA Development Center KK

Tuesday, April 11, 2017

Takeda Pharmaceutical has entered into an agreement for absorption-type company split with its wholly-owned subsidiary which was established in March 2017 (NewCo) and intends to enter into another agreement for joint venture with Pharm Research Associates (PRA(UK)), a subsidiary of PRA Health Sciences, aiming for transferring a part of Takeda Development Center Japan (TDC Japan) businesses to PRA. Takeda and PRA announced the expansion of their partnership to Japan on February 15, 2017.

[Read More]

J&J to acquire Actelion for $30B, spin-out new R&D company

Friday, January 27, 2017

Johnson & Johnson and Actelion have entered into a definitive transaction agreement under which Johnson & Johnson will launch an all-cash tender offer in Switzerland to acquire all of the outstanding shares of Actelion for $280 per share, payable in U.S. dollars, which equates to CHF 280.08 per share as of January 25, 2017. The transaction, which was unanimously approved by the boards of directors of both companies, is expected to be immediately accretive to Johnson & Johnson adjusted earnings per share and accelerate Johnson & Johnson revenue and earnings growth rates. Johnson & Johnson will fund the transaction with cash held outside the U.S.

[Read More]